Shire's First Prescription Eye Drop, Xiidra(TM) (lifitegrast ophthalmic solution) 5% Is Now Available in the U.S.
PR Newswire - Mon Aug 29, 11:40AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that Xiidra(TM) (lifitegrast ophthalmic solution) 5%, a twice-daily prescription eye drop indicated for the treatment of both the signs and symptoms of dry eye disease, is now available by prescription in the United States. An estimated 16 million adults in the U.S. are diagnosed with dry eye, a disease associated with inflammation that may eventually lead to damage to the surface of the eye. An eye care professional can diagnose dry eye disease based on signs and symptoms and determine management options, which could include the use of a prescription treatment. The U.S. Food and Drug Administration (FDA) approved Xiidra on July 11, 2016.
SHPG: 187.18 (-3.04)
Shire and Jennifer Aniston Want to Inspire People to Show Their Eyes Some Love and Help Raise Awareness of Chronic Dry Eye
PR Newswire Europe - Thu Aug 25, 6:01AM CDT
LEXINGTON, Massachusetts, August 25, 2016 /PRNewswire/ --
SHPG: 187.18 (-3.04)
VONVENDI, The First and Only Recombinant Treatment for Adults Affected by Von Willebrand Disease, Launches in the U.S.
PR Newswire - Tue Aug 09, 6:00AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG), continuing on Baxalta's long-standing commitment to the bleeding disorder community, today announced the U.S. launch of VONVENDI [von Willebrand factor (Recombinant)], the only recombinant treatment for adults living with von Willebrand disease (VWD).
SHPG: 187.18 (-3.04)
Top Research Reports for August 4, 2016
Sheraz Mian - Zacks Investment Research - Thu Aug 04, 2:18PM CDT
Top Research Reports for August 4, 2016
CME: 108.35 (+0.51), FISV: 103.05 (+0.11), SHPG: 187.18 (-3.04), AFL: 74.18 (-0.10), CBS: 51.03 (-0.24), CL: 74.34 (-0.16)
Shire Delivers Strong Q2 2016 Revenue Growth; Upgrades Outlook
PR Newswire Europe - Tue Aug 02, 6:02AM CDT
DUBLIN, August 2, 2016 /PRNewswire/ --
SHPG: 187.18 (-3.04)
Should You Buy Shire plc (SHPG) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 7:42AM CDT
Investors are always looking for stocks that are poised to beat at earnings season and Shire plc (SHPG) may be one such company
SHPG: 187.18 (-3.04)
Shire Announces FDA Approval of adynovate with BAXJECT III Reconstitution System
PR Newswire - Mon Aug 01, 6:00AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the U.S. Food and Drug Administration (FDA) has approved the BAXJECT III reconstitution system for ADYNOVATE [Antihemophilic Factor, (Recombinant), PEGylated]. The new system reduces the number of steps in the reconstitution process for hemophilia A patients and caregivers. ADYNOVATE and the diluent will be pre-packaged in the BAXJECT III reconstitution system.
SHPG: 187.18 (-3.04)
Shire Recommends ADS Holders Reject TRC Capital's "Mini-Tender Offer"
PR Newswire - Fri Jul 29, 3:20PM CDT
Shire plc (LSE: SHP) (NASDAQ: SHPG) has been notified of an unsolicited "mini-tender" offer made by TRC Capital Corporation ("TRC Capital"
SHPG: 187.18 (-3.04)
Shire's SHP626 (Volixibat) Receives FDA Fast Track Designation for an Investigational Treatment for Adults Who Have Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis
PR Newswire Europe - Fri Jul 29, 6:01AM CDT
LEXINGTON, Massachusetts, July 29, 2016 /PRNewswire/ --
SHPG: 187.18 (-3.04)
Shire Buys Global Rights to Pfizer's Gastrointestinal Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 4:19PM CDT
Shire plc (SHPG) announced that it will license global rights to all indications of Pfizer's candidate, PF-00547659.
ABT: 42.02 (-0.81), JNJ: 119.34 (-0.13), SHPG: 187.18 (-3.04), PFE: 34.80 (-0.08)
Shire and Kamada Announce FDA Approval of Expanded Label for Self-infusion of GLASSIA for the Treatment of Emphysema Due To Severe AAT Deficiency
PR Newswire - Wed Jun 15, 6:00AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) and Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that the United States Food and Drug Administration (FDA) has approved an expanded label for GLASSIA [Alpha-1 Proteinase Inhibitor (Human)], marking the first treatment for adult patients with emphysema due to severe Alpha-1 Antitrypsin (AAT) Deficiency that can be self-infused at home after appropriate training.
SHPG: 187.18 (-3.04), KMDA: 4.82 (-0.07)
Shire Gets Breakthrough Status for Rare Disease Candidates
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 5:18PM CDT
Shire plc (SHPG) announced that the FDA has granted Breakthrough Therapy Designation to two candidates in its rare diseases pipeline.
ABT: 42.02 (-0.81), SHPG: 187.18 (-3.04), PFE: 34.80 (-0.08), BMY: 57.39 (+0.15)
Shire Announces Completion of Decentralized Procedure in Europe for Immunoglobulin Treatment Cuvitru
PR Newswire Europe - Fri Jun 10, 2:12PM CDT
ZUG, Switzerland, June 10, 2016 /PRNewswire/ --
SHPG: 187.18 (-3.04)